Share
Two pharmaceutical companies will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical development as a potential treatment for acromegaly Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration...
Share
Variants in genes that mediate fibroblast growth factor 21 – a hormone secreted by the liver that acts to regulate the body’s response to starvation – have for the first time been linked to severe insulin resistance, according to a paper recently published in the Journal of the Endocrine Society. Researchers led by Stephen Stone,...
Share
Girls with anorexia nervosa can have stunted growth and may not reach their full height potential, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Anorexia nervosa is a condition in which a person loses an unhealthy amount of weight on purpose by dieting, sometimes along with excessive exercise, binge eating, and/or purging behaviors. People with anorexia nervosa have an intense fear of...
Share
The U.S. Food and Drug Administration (FDA) last month approved leuprolide acetate for injectable suspension for the treatment of pediatric patients two years of age and older with central precocious puberty (CPP). Tolmar Pharmaceuticals is marketing the drug as Fensolvi. Leuprolide acetate is the most widely used treatment for CPP. Fensolvi utilizes a proprietary polymeric gel...
Share
A review recently published in The Journal of Clinical Endocrinology & Metabolism looks at how genome-wide association studies (GWASs) have impacted the medical community’s understanding of the underlying biology of human growth. The paper, by Michael H. Guo, of the Broad Institute of MIT and Harvard in Cambridge, Mass., et al., summarizes key findings of...
Share
A French study published in the Journal of the Endocrine Society reveals myriad complications that many acromegaly patients face after they’ve been successfully treated. Lead researcher Frederic Castinetti, MD, PhD, discusses his research and why follow-up may still be required once a patient is “cured.” Last December, a paper appeared in the Journal of the Endocrine Society...
Share
Cancer incidence rates are slightly elevated in patients with acromegaly, according to a meta-analysis recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Jens Otto Lunde Jørgensen, MD, DMSc, of the Department of Endocrinology and Internal Medicine at Aarhus University Hospital in Norrebrogade, Denmark point out that acromegaly has been associated...
Share
A paper published recently in the Journal of the Endocrine Society details a case of a woman with acromegaly-like features, but she did not have excess growth hormone (GH) secretion. The authors use the case to show that differential diagnoses should be considered in these patients with “pseudoacromegaly” or “acromegaloidism.” The paper, by Per Dahlqvist,...
